Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
NSE:BIOFILCHEM'
s PEG Ratio Range Over the Past 10 Years
Min: 0.23 Med: 4.32 Max: 579.11
Current: 4.64
During the past 13 years, Biofil Chemicals & Pharmaceuticals's highest PEG Ratio was 579.11. The lowest was 0.23. And the median was 4.32.
NSE:BIOFILCHEM's PEG Ratio is ranked worse than 77.43% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.775
vs NSE:BIOFILCHEM: 4.64
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Biofil Chemicals & Pharmaceuticals PEG Ratio Related Terms
Biofil Chemicals & Pharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals PEG Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) has a PEG Ratio of 4.69 as of Jul. 22, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. This is near median its historical median of 4.32. Over the past decade, Biofil Chemicals & Pharmaceuticals' PEG Ratio has ranged from 0.23 to 579.11. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #271 out of 350 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is Biofil Chemicals & Pharmaceuticals' PEG Ratio too high?
Biofil Chemicals & Pharmaceuticals' current PEG Ratio of 4.69 is near median its 10-year median of 4.32. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 579.11. The Drug Manufacturers industry median PEG Ratio is 1.78. Biofil Chemicals & Pharmaceuticals' value of 4.69 is 164.2% above this industry median. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #271 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #271 out of 350 companies for PEG Ratio. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median PEG Ratio is 1.78. Biofil Chemicals & Pharmaceuticals' value of 4.69 is 164.2% above this benchmark. Historically, Biofil Chemicals & Pharmaceuticals' own PEG Ratio has ranged from 0.23 to 579.11 over the past decade. While the company's 10-year median is 4.32 vs. the industry median of 1.78, Biofil Chemicals & Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.78, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofil Chemicals & Pharmaceuticals's current PEG Ratio of 4.69 is 164.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current PEG Ratio is 4.69, which is near median its own 10-year median of 4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹42.26, compared to a current price of ₹33.68 — trading 20.3% below its estimated fair value. The current PEG Ratio is 4.69, which is near median its 10-year median of 4.32 and 164.2% above the Drug Manufacturers industry median of 1.78. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM), the current PEG Ratio is 4.69 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (NSE:BIOFILCHEM) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹33.68 is trading 20.3% below its estimated GF Value™ of ₹42.26.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:BIOFILCHEM:
PEG Ratio: 4.69 (near median its 10-year median of 4.32)
GF Value™: ₹42.26 vs. price of ₹33.68 (20.3% below fair value)
Industry Position: 164.2% above the Drug Manufacturers median (#271 of 350)
No single metric tells the full story. See the NSE:BIOFILCHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
74GF Score
Get the complete analysis for NSE:BIOFILCHEM
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOFILCHEM has been successfully added to your 
